Azithromycin and ciprofloxacin: A possible synergistic combination against Pseudomonas aeruginosa biofilm-associated urinary tract infections

International Journal of Antimicrobial Agents

Volumn 45, Issue 4, 2015, Pages 359-367

  Saini, Hina ^a   Chhibber, Sanjay ^a   Harjai, Kusum ^a  

^a PANJAB UNIVERSITY   (India)

Author keywords

Cytokines; FICI; Fractional inhibitory concentration index; ntibiofilm; Pathology index factors

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZITHROMYCIN; CIPROFLOXACIN; COTRIMOXAZOLE; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 2; MALONALDEHYDE; NITRIC OXIDE; ANTIINFECTIVE AGENT; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CELL; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL STRAIN; BACTERIOLOGY; BACTERIUM ISOLATE; BIOFILM; BLADDER; COMBINATION CHEMOTHERAPY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; DRUG DETERMINATION; DRUG EFFICACY; FEMALE; FRACTIONAL INHIBITORY CONCENTRATION INDEX; HISTOPATHOLOGY; HUMAN; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MOUSE; NONHUMAN; PLANKTON; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS AERUGINOSA STRAIN PAO1; PYELONEPHRITIS; TIME KILL ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; URINARY TRACT INFECTION; ANIMAL; CONFOCAL MICROSCOPY; CYTOCHEMISTRY; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; KIDNEY; MICROBIAL SENSITIVITY TEST; MICROBIAL VIABILITY; MICROBIOLOGY; PATHOLOGY; PHYSIOLOGY; PROCEDURES; PSEUDOMONAS INFECTIONS; URINARY TRACT INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BACTERIAL LOAD; BIOFILMS; CIPROFLOXACIN; CYTOKINES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; HISTOCYTOCHEMISTRY; KIDNEY; MICE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; MICROSCOPY, CONFOCAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; TREATMENT OUTCOME; URINARY BLADDER; URINARY TRACT INFECTIONS;

EID: 84925488603     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2014.11.008     Document Type: Article

References (28)

1. V. Lazãr, and M.C. Chifiriuc Medical significance and new therapeutical strategies for biofilm associated infections Roum Arch Microbiol Immunol 69 2010 125 138
2. P.S. Guiton, C.S. Hung, L.E. Hancock, M.G. Caparon, and S.J. Hultgren Enterococcal biofilm formation and virulence in an optimized murine model of foreign body-associated urinary tract infections Infect Immun 78 2010 4166 4175
3. K. Tateda, R. Comte, J.C. Pechere, T. Kohler, K. Yamaguchi, and C.V. Delden Azithromycin inhibits quorum sensing in Pseudomonas aeruginosa Antimicrob Agents Chemother 45 2001 1930 1933
4. Y. Nalca, L. Jänsch, F. Bredenbruch, R. Geffers, J. Buer, and S. Häussler Quorum-sensing antagonistic activities of azithromycin in Pseudomonas aeruginosa PAO1: a global approach Antimicrob Agents Chemother 50 2006 1680 1688
5. A. Bala, R. Kumar, and K. Harjai Inhibition of quorum sensing in Pseudomonas aeruginosa by azithromycin and its effectiveness in urinary tract infections J Med Microbiol 60 2011 300 306
6. S. Kanoh, and B.K. Rubin Mechanisms of action and clinical application of macrolides as immunomodulatory medications Clin Microbiol Rev 23 2010 590 615
7. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically Approved standard - 7th ed. 2006 CLSI Wayne, PA (Document M7-A7)
8. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing: twenty-second informational supplement 2012 CLSI Wayne, PA (Document M100-S22)
9. M.M. Sopirala, J.E. Mangino, W.A. Gebreyes, B. Biller, T. Bannerman, and J-M. Balada-Llasat Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii Antimicrob Agents Chemother 54 2010 4678 4683
10. E. Mataraci, and S. Dosler In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms Antimicrob Agents Chemother 56 2012 6366 6371
11. S.K. Pillai, and R.C. Moellering Jr. Eliopoulos GM. Antimicrobial combinations V. Lorian, Antibiotics in laboratory medicine 5th ed. 2005 Lippincott Williams & Wilkins Philadelphia, PA 365 440
12. R. Mittal, S. Chhibber, S. Sharma, and K. Harjai Macrophage inflammatory protein-2, neutrophil recruitment and bacterial persistence in an experimental mouse model of urinary tract infection Microbe Infect 6 2004 1326 1332
13. K. Harjai, R. Mittal, S. Chhibber, and S. Sharma Contribution of Tamm-Horsfall protein to the virulence of Pseudomonas aeruginosa in relation to urinary tract infections Microbe Infect 7 2005 132 137
14. U.C. Garg, N.K. Ganguly, S. Sharma, R.N. Chakravarti, and R.K. Bhatnagar Quantitative histopathological methods for evaluation of experimental ascending pyelonephritis Med Sci Res 15 1987 367 368
15. M. Anjaneyulu, and K. Chopra Effect of irbesartan on the antioxidant defence system and nitric oxide release in diabetic rat kidney Am J Nephrol 24 2004 488 496
16. K.A. Rockett, M.M. Awburn, E.J. Rockett, W.B. Cowden, and I.A. Clark Possible role of nitric oxide in malarial immunosuppression Parasite Immunol 16 1994 243 249
17. J.M. Buyck, P. Plésiat, H. Traore, F. Vanderbist, P.M. Tulkens, and F.V. Bambeke Increased susceptibility of Pseudomonas aeruginosa to macrolides and ketolides in eukaryotic cell culture media and biological fluids due to decreased expression of oprM and increased outer-membrane permeability Clin Infect Dis 55 2012 534 542
18. S.A. Mehnert-Kay Diagnosis and management of uncomplicated urinary tract infections Am Fam Physician 72 2005 451 456
19. R.J. Gillis, K.G. White, K-H. Choi, V.E. Wagner, H.P. Schweizer, and B.H. Iglewski Molecular basis of azithromycin-resistant Pseudomonas aeruginosa biofilms Antimicrob Agents Chemother 49 2005 3858 3867
20. T. Wagner, G. Soong, S. Sokol, L. Saiman, and A. Prince Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients Chest 128 2005 912 919
21. L. Saiman, Y. Chen, P.S. Gabriel, and C. Knirsch Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis Antimicrob Agents Chemother 46 2002 1105 1107
22. H. Kobayashi, O. Kobayashi, and S. Kawai Pathogenesis and clinical manifestations of chronic colonization by Pseudomonas aeruginosa and its biofilms in the airway tract J Infect Chemother 15 2009 125 142
23. D.P. Nicolau, M.A. Banevicius, C.H. Nightingale, and R. Quintiliani Beneficial effect of adjunctive azithromycin in treatment of mucoid Pseudomonas aeruginosa pneumonia in the murine model Antimicrob Agents Chemother 43 1999 3033 3035
24. M. Meyer, F. Huaux, X. Gavilanes, S. van den Brûle, P. Lebecque, and S. Lo Re Azithromycin reduces exaggerated cytokine production by M1 alveolar macrophages in cystic fibrosis Am J Respir Cell Mol Biol 41 2009 590 602
25. M.J. Parnham, V.E. Haber, E.J. Giamarellos-Bourboulis, G. Perletti, G.M. Verleden, and R. Vos Azithromycin: mechanisms of action and their relevance for clinical applications Pharmacol Ther 143 2014 225 245
26. A. Majhi, K. Kundu, R. Adhikary, M. Banerjee, S. Mahanti, and A. Basu Combination therapy with ampicillin and azithromycin in an experimental pneumococcal pneumonia is bactericidal and effective in down regulating inflammation in mice J Inflamm (Lond) 11 2014 5
27. V. Magri, E. Montanari, V. Skerk, A. Markotic, E. Marras, and A. Restelli Fluoroquinolone-macrolide combination therapy for chronic bacterial prostatitis: retrospective analysis of pathogen eradication rates, inflammatory findings and sexual dysfunction Asian J Androl 13 2011 819 827
28. A. Kolumbić Lakoš, V. Škerk, G. Maleković, T. Dujnić Špoljarević, D. Kovačić, and M. Pasini A switch therapy protocol with intravenous azithromycin and ciprofloxacin combination for severe, relapsing chronic bacterial prostatitis: a prospective non-comparative pilot study Medicus 21 2012 153 158